Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Sarcoma 3Gastrointestinal Stromal Tumors 2Piebaldism 1Osteosarcoma 1Histiocytoma, Malignant Fibrous 1Diabetes Mellitus, Insulin-Dependent, 12 1Dermatofibrosarcoma 1Chondrosarcoma 1

Interventions

Imatinib Mesylate 71Sunitinib 31regorafenib 17nilotinib 15ripretinib 13avapritinib 7Laparoscopy 5Ipilimumab 5Dasatinib 5spartalizumab 4CTLA-4 Antigen 4Blood Specimen Collection 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Oxaliplatin 3Observation 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Biopsy 3Bevacizumab 3trametinib 2tanespimycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × envafolimab × Sarcoma × Clear all
NCT07559864 2026-04-30

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
100 enrolled
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

NCT06772233 2025-07-31

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

Peking University

Phase 2 Not yet recruiting
100 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡